Abstract: Vaccine of preferential administration via mucous membranes, for the control of diseases generated by infectious agents that use heparan sulfate (HS) as a cellular receptor consisting of an immunogenic formulation for veterinary use, comprising an antigen whose cellular receptor is heparan sulfate (HS), a vehicle for oral, intranasal or parenteral administration, wherein said vehicle corresponds to D-glucosamine and functionalized N-acetyl-D-glucosamine biopolymers, with sulfur atoms, and/or functionalized chitosan biopolymer, with sulfur atoms, and where the antigen is microencapsulated by said types of functionalized biopolymers.

Abstract: The present invention relates to antibodies that are heterodimeric and bind human PD-L1 and human TIM-3, and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.

Abstract: Described herein are methods and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), Crohn's Disease (CD), ulcerative colitis (UC) and medically refractive-ulcerative colitis (MR-UC). In particular, disclosed are anti-TL1A antibodies useful for the treatment of IBD.

Abstract: In alternative embodiments, the invention provides a “triple combination” therapy for treating, ameliorating and preventing Crohn's Disease (or Crohn syndrome, terminal or distal ileitis or regional enteritis) or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne's disease, including genetically-predisposed and chronic disorders, where the microbial or bacterial flora of the bowel is at least one causative or symptom-producing factor; and compositions for practicing same. In alternative embodiments, methods and compositions of the invention comprise or comprise use of therapies, medications, formulations and pharmaceuticals comprising active agents that can suppress or eradicate the microbiota super-infection that causes Crohn's Disease or paratuberculosis infection in mammals.

Abstract: A method for treating a patient comprising: (a) providing a composition comprising a population of T cells expressing both a chimeric antigen receptor (CAR) and a T cell receptor specific for a cytomegalovirus (CMV) antigen; (b) administering the composition to the patient; and (c) administering to the patient a viral vector encoding: (i) CMV pp65 and (ii) a fusion protein comprising exon 4 of CMV protein IE1 (e4) and exon 5 of CMV protein IE2 (e5) either prior to or subsequent to administering the composition comprising a population of T cells to the patient is described.

Abstract: Antibody variants originating from the monoclonal antibody 13C6, and wherein the N-glycosylation site within the constant region of the heavy chain contains a glycan that is either wild-type or largely devoid of fucose residues, will bind Ebola virus glycoprotein and provide surprising efficacy in treating animals or humans infected with Ebola virus when used in combination with one or more additional anti-Ebola mAbs. Such antibody cocktails are vastly superior to other known monoclonal antibodies or monoclonal antibody combinations in treating animals and humans infected with the Ebola virus.

Abstract: Metal-organic frameworks for drug delivery systems, therapeutic compositions including the metal-organic frameworks, and method of treating cancer using the therapeutic compositions are disclosed. According to some embodiments, a method of treating cancer in a mammal may include: providing a therapeutic composition containing a nanocarrier with a drug-loaded metal organic framework; delivering the therapeutic composition to the mammal; allowing the nanocarrier to circulate throughout a circulatory system of the mammal for a time sufficient to allow aggregation of a therapeutic quantity of the nanocarrier at a treatment area; and applying ultrasound to the treatment area such that the nanocarrier releases the drug in the treatment area.

Abstract: Disclosed herein are anti-RGMa antibodies and methods of using these antibodies to treat multiple sclerosis, including relapsing forms of multiple sclerosis such as relapsing-remitting multiple sclerosis or relapsing-secondary progressive multiple sclerosis.

Abstract: Some aspects of this disclosure relate to a method of treating an ophthalmic disease affecting an eye of a patient comprising forming a covalently-crosslinked hydrogel for controlled release of a therapeutic agent.

Abstract: Oral thin film dosage form of a stable dispersion of non-solubilized amorphous or partially amorphous active agent(s), having a mean particle size diameter D50 equal or less than 250 ?m, that remains uniformly distributed within a film matrix and contains at least one film forming polymer, and optional pharmaceutically-acceptable excipients, such as diluents, plasticizers, surfactants, sweeteners, and taste-masking agent(s), are prepared by a process including first providing the active agent in an amorphous particle form having a mean particle size diameter D50 equal or less than 250 ?m. Next, the active agent is suspended in a liquid film-forming formulation without dissolving the active agent. Therefore, the solvent is removed to form a film.

Abstract: The present invention relates to a stabilized pharmaceutical preparation of R27T, the preparation comprising a human interferon beta variant (R27T), an acetate buffer, arginine, trehalose, Poloxamer 188, and methionine. The stabilized R27T pharmaceutical preparation according to the present invention is obtained by the development of a preparation having a novel composition through the substitution of mannitol with trehalose in the composition of a preparation containing mannitol, which was previously studied by the present inventors.

Abstract: Provided herein are branched oligonucleotides exhibiting efficient and specific tissue distribution, cellular uptake, minimum immune response and off-target effects, without formulation.

Abstract: The subject invention is based upon the discovery that a wide variety of pharmaceutical agents can be delivered into the skin, fingernails, and toenails of patients by dissolving or dispersing the pharmaceutical agent in a solvent system which is comprised of a combination of an alkyl lactate and Simmondsia chinesis seed oil. The subject invention more specifically discloses a pharmaceutical serum which is comprised of (1) an alkyl lactate, wherein the alkyl group in the alkyl lactate contains from 2 to about 12 carbon atoms, (2) Simmondsia chinesis seed oil, and (3) a pharmaceutical agent. Some representative examples of pharmaceutical agent which can be incorporated into the pharmaceutical serums of this invention include, hormones, growth factors (cytokines), antimicrobials, antibacterials, antibiotics, non-steroidal anti-inflammatory agents, immunodilators, anesthetics, plant extracts, vitamins, corticosteroids, hair growth stimulants, and the like.

Abstract: The present application provides bifunctional compounds of Formula (I): or Targeting Ligand or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as protein degradation inducing moieties for bromodomain-containing protein 9 (BRD9). The present application also provides methods for the targeted degradation of BRD9 through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to BRD9 which can be utilized in the treatment of disorders modulated by BRD9.

Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.

Abstract: Described herein are compositions and methods for treating or preventing an injury associated with transplant. Specifically, the disclosure provides a composition for treating or preventing an injury associated with transplantation, comprising (a) a targeted inhibitor molecule wherein the targeted inhibitor molecule comprises a targeting portion and an inhibitor portion, wherein the molecule inhibits complement pathways, and (b) a sub-therapeutic dose of an immunosuppressant agent. Further provided are methods of treating or preventing an injury associated with transplantation with activated complement by using the compositions.

Abstract: A bifunctional polypeptide comprising a specific binding partner for a peptide-MHC epitope, such as an antibody or T cell receptor, and an immune effector, such as an antibody or a cytokine, the immune effector part being linked to the N-terminus of the peptide-MHC binding part.

Abstract: Disclosed is an advancement in provoked chemical cleavage. Thereby the invention provides the use of a diene as a chemically cleavable group attached to a Construct, and the use of a dienophile to provoke the release of the Construct by allowing the diene to react with a dienophile capable of undergoing an inverse electron demand Diels Alder reaction with the diene. The invention includes a kit for releasing a Construct CA bound to a Trigger TR, the kit comprising a tetrazine and a dienophile, wherein the Trigger is the tetrazine. The invention also includes the use of the formation of a pyridazine by reacting a tetrazine comprising a Construct CA bound thereto and a dienophile, as a chemical tool for the release, in a chemical, biological or physiological environment, of said Construct.

Abstract: A method for treating a burn, lesion, lacuna, or wound comprising contacting the burn, lesion, or wound with a chitosan-functionalized silica sphere (“CHI-HSS”). Chitosan-functionalized silica spheres and pharmaceutical compositions containing them.

Abstract: DNA-targeted nanocarriers for encapsulating an active agent and delivering it to extracellular DNA are provided. The nanocarriers, for example, polymeric particles, liposomes, and multilamellar vesicles have targeting moiety that targets DNA conjugated thereto. The targeting moiety that targets DNA is typically an antibody, or variant, fragment, or fusion protein derived therefrom that binds to DNA or nucleosomes. The targeting moiety can be a circulating autoantibody that binds DNA such as those commonly found in patients with SLE. In some embodiments, the targeting moiety is antibody 3E10 or a variant, fragment, or fusion protein derived therefrom. Pharmaceutical compositions, methods of use, and dosage regimens are also provided.

Abstract: A delivery vehicle which comprises a nucleic acid construct, wherein the nucleic acid construct comprises (i) an enhancer which specifically drives gene expression in cells of the entorhinal cortex (ii) a promoter; and (iii) a therapeutic gene, wherein said enhancer, promoter and therapeutic gene are operatively linked, said enhancer and therapeutic gene are heterologous, and said delivery vehicle is suitable for delivery of the nucleic acid construct to the brain of a mammal.

Abstract: Provided include materials and methods for treating Hemophilia A in a subject ex vivo or in vivo. Also provided include materials and methods for knocking in a FVIII-encoding gene in a genome, in particular the locus of albumin gene.

Abstract: Provided herein are recombinant expression vector systems for expression by stem cells that allow for selective elimination of stem cell-derived tumorigenic cells, while preserving stem cell-derived therapeutic cells. The systems provided herein provide a means by which modified stem cells can be safely transplanted into subjects. In exemplary embodiments, the system comprises at least two suicide genes, one of which is specifically inactivated in cells exhibiting the desired phenotype and one of which is activated when the cell comprising the recombinant expression vector system behaves similarly to or the same as a tumor cell.

Abstract: Disclosed herein are novel nucleic acid molecules which encode novel polypeptides for use in treating polyglutamine diseases such as Huntington's disease. The polypeptides of the invention exhibit reduced immunotoxity in vivo and may have utility in sustained (mid- or long-term) expression in vivo. Also disclosed are methods for the treatment of polyglutamine diseases, such as Huntington's disease and the use of nucleic acids and polypeptides of the invention in medical therapy. Gene therapy methods and compositions, such as AAV vectors for use in gene therapy methods are also disclosed.

Abstract: Provided herein are non-invasive in vivo imaging methods to evaluate efficacy of a therapeutic intervention for neuromuscular diseases by determining the level and/or localization of a detectable marker that is influenced by another protein which is a target of the therapeutic intervention. Non-invasive imaging methods disclosed herein can involve in vivo molecular imaging such as PET or SPECT, and/or morphological imaging such as MRI or CT.

Abstract: The present invention relates to compositions and methods for reducing the risk and/or extent of radiocontrast-induced nephropathy (“RIN”) for kidney-imaging procedures that employ a radiocontrast medium. It is based, at least in part, on the discovery that, in a renal tubular cell line, radiocontrast induced inflammatory upregulation and cell injury could be reduced by calcineurin inhibitors FK506 and cyclosporine.

Abstract: A biocompatible magnetic material containing an iron oxide nanoparticle and one or more biocompatible polymers, each having formula (I) below, covalently bonded to the iron oxide nanoparticle: in which each of variables R, L, x, and y is defined herein, the biocompatible magnetic material contains 4-15% Fe(II) ions relative to the total iron ions. Also disclosed in a method of preparing the biocompatible magnetic material.

Abstract: A functional gadolinium contrast agent comprising a gadolinium cation and a ligand secured to the gadolinium cation is disclosed, the ligand comprising a reactive group capable of bonding to a capture substrate. A method of removing gadolinium contrast agents from a patient is disclosed, the method comprising providing a gadolinium contrast agent containing a reactive group; providing a capture substrate for insertion into a patient's bloodstream; administering the gadolinium contrast agent to the patient; conducting a magnetic resonance imaging procedure; and sequestering the gadolinium contrast agent on the capture substrate. A system for removing gadolinium contrast agents is also disclosed.

Abstract: A polymer-metal oxide complex, comprising a metal oxide particle located at the core and a polymer modified on the surface of the metal oxide particle, the polymer being provided with functional groups capable of bonding with a metal in the metal oxide, the density of the binding sites of the polymer and the surface of the metal oxide particle being greater than two sites/square nanometer. Also disclosed are a preparation method for the polymer-metal oxide complex, and applications of the polymer-metal oxide complex as a nuclear magnetic resonance contrast agent and as an iron supplement. The polymer-metal oxide complex has a significantly extended in vivo circulation time and effectively overcomes the defect that existing contrast agents cause hypersensitivity, which in addition to the superparamagnetic and iron metabolism participation functions of the complex, enables the complex to be applied as a magnetic resonance imaging contrast agent and as an iron supplement treating iron-deficiency anaemia.

Abstract: The present invention provides nanocarrier compositions, for example, copper sulfide perfluorocarbon nanocarrier compositions, and methods of making the same. The compositions are useful for imaging, diagnostics, therapy and for other uses.

Abstract: A method of forming a plurality of microbubbles, wherein the method disposes in a sealed container comprising a first volume at ambient pressure, a second volume of a mixture comprising one or more microbubble stabilizing materials. The first volume is greater than said second volume. The method further comprises sealing said container, introducing a gas into said sealed container, and shaking the container to form said plurality of microbubbles.

Abstract: The present invention relates to 18F-labeled compounds suitable for positron emission tomography (PET) imaging. The invention further relates to the use of these compounds for carrying out PET scans, imaging the indoleamine 2,3-dioxygenase, pathway, predicting the responsiveness of a subject with a solid tumor to therapies including immunotherapy such as PD-1/PD-L1 inhibition, and determining whether a solid tumor in a subject contains tumor-infiltrating immune cells.

Abstract: An example luminaire includes a white light source (e.g. LEDs emitting white light in a region of the CIE color chart within three Macadam ellipses below the black body curve) and a violet light source emitting light in a wavelength range of approximately 380 nm to 450 nm (e.g. 405 nm LEDs) for deactivating bacteria, such as Methicillin-Resistant Staphylococcus Aureus (MRSA) on a surface exposed to illumination from the luminaire. A controller coupled to the sources pulses the violet light source at periodic intervals or at random times. When ON, the violet source emits light for deactivating bacteria at an intensity higher than the concurrent intensity of the white light.

Abstract: A method, system and apparatus are described for decontaminating small enclosures, semi-enclosed and closed areas of pathogens by using a very dry mist comprising ionized hydrogen peroxide. The system can be controlled manually by the user, or by a remote connection, such as a wireless network connection. The method includes use of a handheld, point-and-spray device that sprays a very dry mist comprising ionized hydrogen peroxide under manual or automated control.

Abstract: An air treatment article is provided, comprising: a semipermeable barrier and a plurality of multi-staged non-film forming polymer abatement particles having a core polymer and at least one shell polymer; wherein the core polymer accounts for 1 to 25 wt % of the weight of the non-film forming polymer abatement particles; wherein the semipermeable barrier is disposed between an air atmosphere and the non-film forming polymer abatement particles; wherein the semipermeable barrier impedes passage therethrough by the non-film forming polymer abatement particles; wherein the semipermeable barrier permits passage therethrough by a for-treatment air containing a contaminant such that the for-treatment air can make contact with the non-film forming polymer abatement particles; wherein the non-film forming polymer abatement particles have an affinity for the contaminant.

Abstract: A fragrance delivery apparatus contains: a body, a fan, a power base, and a case. The body includes an accommodation chamber defined therein, a receiving groove formed above the accommodation chamber, an air vent arranged on a first side of the body and communicating between the accommodation chamber and the receiving groove, and multiple elongated orifices formed on a second side of the body opposite to the first side of the body and communicating with the accommodation chamber. The fan is accommodated in the accommodation chamber and draws external gas from the multiple elongated orifices. The power base is connected with the body and shields the accommodation chamber, and the power base is configured to supply power and is electrically connected with the fan. The case is removably connected outside the body and includes a spray nozzle which is in communication with the receiving groove.

Abstract: A scent air purifier contains a body, a fan, a filter element, a holder, a circuit control unit, a case removable from the body. The body includes an accommodation chamber, a receiving groove, and a first vent. The accommodation chamber is defined in the body, the receiving groove is located above the accommodation chamber, and the first vent communicates with the accommodation chamber and the receiving groove. The fan is accommodated in the accommodation chamber. The filter element is connected below the accommodation chamber and communicates with air from an external environment outside the body so that the fan delivers the air to flow through the first vent and the receiving groove, after drawing the air from the external environment. The holder is connected with the body, and the circuit control unit is housed in the holder and is electrically connected with a power source and the fan.

Abstract: A scent diffusing system electrically charged in a wireless manner contains: a wireless charger and an aroma diffuser. The aroma diffuser includes a case, an air guide holder, a wireless charging receiver, and an air conveyor. The case has an open segment and a receiving chamber defined in the open segment. The air conveyor is accommodated in a bottom of the air guide holder, and the air guide holder is connected above the open segment of the case. The wireless charging receiver is accommodated in the receiving chamber, and the air conveyor is electrically connected with the wireless charging receiver. The aromatic element is received in the air guide holder of the aroma diffuser.

Abstract: A laminate patchable a living body includes a pressure-sensitive adhesive layer for patching to the living body and a substrate layer disposed on a one-side surface in a thickness direction of the pressure-sensitive adhesive layer and supporting the pressure-sensitive adhesive layer. The pressure-sensitive adhesive layer contains a first carboxylic acid ester and the substrate layer contains a second carboxylic acid ester.

Abstract: A curable composition apportioned between at least one Part A and at least one Part B, the Parts sealed within barrier means in manner to prevent contamination thereof, the composition comprising: (i) one or more alkenyl-containing prepolymers having at least one alkenyl moiety per molecule, (ii) one or more SiH-containing prepolymers having at least one SiH unit per molecule, and additionally: (iii) a catalyst for curing by addition of alkenyl-containing prepolymer (i) to SiH-containing prepolymer (ii), wherein the at least one Part A and at least one Part B are provided within or upon at least two respective receptacles or supports and are adapted to be dispensed or released therefrom in cooperative manner facilitating intimate contact and curing thereof, wherein the receptacle(s) or support(s) for at least one of Part A and Part B is thermally stable at elevated temperature of 123 C for a period in excess of 18 hours, methods for preparing the composition, methods for sterilisation thereof, medical and non

Abstract: Provided are the use of poly(N-isopropylacrylamide-co-butyl methacrylate) in preparing an embolism material for blood vessels, an embolism material for blood vessels and the use thereof in preparation of drugs. The embolism material for blood vessels comprises poly(N-isopropylacrylamide-co-butyl methacrylate) and a dispersion medium consisting of an electrolyte, a contrast agent, a pH regulator and water. The concentrations of the polymer, electrolyte and contrast agent are respectively 5-30 mg/ml, 0.1-30 mg/ml and 100-350 mg/ml based on iodine. The embolism material for blood vessels is suitable for embolization therapy of tumors in hypervascular and parenchymal visceral organs.

Abstract: A method of hemostasis includes the step of applying a hemostatic agent to an affected site of a subject, the hemostatic agent consisting of a first agent comprising a gelatin derivative having a hydrophobic group bonded to the gelatin via an imino group, wherein the gelatin derivative has (a) a weight average molecular weight of from 10,000 to 50,000, (b) the hydrophobic group, which is an alkyl group having 6 to 18 carbon atoms; and (c) a molar ratio of imino group/amino group of the gelatin derivative ranging from 1/99 to 30/70; and a second agent including a crosslinking agent for the gelatin derivative.

Abstract: Antimicrobial metal ion coatings and implants including them. In particular, described herein are coatings including an anodic metal (e.g., silver and/or zinc and/or copper) that is co-deposited with a cathodic metal (e.g., palladium, platinum, gold, molybdenum, titanium, iridium, osmium, rhodium, manganese, niobium or rhenium) on a substrate so that the anodic metal is galvanically released as antimicrobial ions when the apparatus is exposed to a bodily fluid. The anodic metal may be at least about 25 percent by volume of the coating, resulting in a network of anodic metal with less than 20% of the anodic metal in the coating fully encapsulated by cathodic metal. The implant may be configured as an implant such as a bone-screw or intramedullary rod-like body configured to receive a treatment cartridge having a coating as described.

Abstract: The present invention provides scaffolds that include a polymer and a cyclic peptide ligand. The peptide ligand increases the attachment of endothelial cells and/or progenitor cells to the scaffold. The present invention also provides engineered tissues that include the provided scaffolds. The present invention also provides coatings that include a coating polymer and a cyclic peptide ligand. The present invention also provides methods of improving endothelialization and vascularization of endothelial cells and/or progenitor cells for tissue regeneration in a subject and of repairing bone defects in a subject, by implanting a provided scaffold.

Abstract: The present invention provides a composition comprising specific self-assembling peptides, which are capable of self-assembly at a pH below 7.5 and at least physiologic ionic strength, e.g., PI 1-4. PI 1-8, PI 1-14, PI 1-13, PI 1-12, PI 1-28, PI 1-29, PI 1-2, PI 1-5, PI 1-17, PI 1-19, PI 1-20, PI 1-12, PI 1-16, PI 1-18, PI 1-26 or PI 1-31 for use in treating an oral disease selected from the group consisting of gingivitis, periodontitis and/or peri-implantitis in a subject. Said composition may be used, after suitable cleaning procedures, for filling pockets formed adjacent to teeth in said diseases, which enhances tissue regeneration. The composition may be suitable for controlled release of an active agent, e.g., an antimicrobial or antibiotic agent. The invention also provides a kit suitable for said treatment further comprising self-assembling peptides suitable for forming a second layer on top of the first composition.

Abstract: The present invention is encompassed in the field of biomedicine and more specifically tissue engineering. It relates specifically to an in vitro method for preparing an artificial tissue, to the artificial tissue obtainable by said method and to the use of this artificial tissue to partially or completely increase, restore or replace the functional activity of a damaged tissue or organ.

Abstract: The invention relates to a polymer-clay composite material comprising clay nanoparticles and a polymer, and wherein (a) the polymer comprises phosphate and/or phosphonate ligands; or (b) the polymer-clay composite further comprises linker molecules comprising a phosphate or phosphonate ligand, wherein the linker molecules are arranged to be anchored to the polymer. The invention further relates to organoclays, BMP-clay composite material. Uses, treatments, and manufacturer of the material are also provided.

Abstract: Composites and scaffolds suitable for bone void filling comprising at least a recombinant gelatin and hydroxyapatite in which the recombinant gelatin comprises glutamic and aspartic acid residues that are distributed homogeneously along a gelatin chain, wherein: (i) the recombinant gelatin comprises a total of at least a 8% glutamic and/or aspartic acids amount per 60 amino acids in row with a standard deviation of at most 1.6; (ii) the hydroxyapatite is obtained by precipitation in the presence of the recombinant gelatin.

Abstract: The present invention relates to methods of fabricating PCU/UHMWPE blended filaments and medical implantable structures using 3D printing of polymeric material, such as PCU/UHMWPE blend structures. The 3D printer dispenses said polymeric material in a layer-by-layer manner to create said medical implant. Polymeric material is dispensed at up to 100% infill. In one embodiment, the layer-by-layer dispensing is at a reduced speed for the bottom and top 1 to 10 layers.

Abstract: A hybrid scaffold is disclosed which is made of materials that define peripheral layers designed to interface with the tissues in the implant site and one or more intermediate layers. The materials are combined to give the scaffold mechanical properties suitable for withstanding the stresses of the implant site.